PL4069686T3 - Agonista receptora glp-1 - Google Patents
Agonista receptora glp-1Info
- Publication number
- PL4069686T3 PL4069686T3 PL20895723.3T PL20895723T PL4069686T3 PL 4069686 T3 PL4069686 T3 PL 4069686T3 PL 20895723 T PL20895723 T PL 20895723T PL 4069686 T3 PL4069686 T3 PL 4069686T3
- Authority
- PL
- Poland
- Prior art keywords
- glp
- receptor agonist
- agonist
- receptor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/10—Radicals substituted by halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20190158410 | 2019-12-02 | ||
| PCT/KR2020/017405 WO2021112538A1 (en) | 2019-12-02 | 2020-12-01 | Glp-1 receptor agonist |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4069686T3 true PL4069686T3 (pl) | 2025-04-28 |
Family
ID=76221772
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL20895723.3T PL4069686T3 (pl) | 2019-12-02 | 2020-12-01 | Agonista receptora glp-1 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US12421205B2 (pl) |
| EP (1) | EP4069686B1 (pl) |
| KR (1) | KR20210069000A (pl) |
| CN (1) | CN114761395B (pl) |
| ES (1) | ES3010351T3 (pl) |
| HU (1) | HUE070634T2 (pl) |
| PL (1) | PL4069686T3 (pl) |
| WO (1) | WO2021112538A1 (pl) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019382642B2 (en) | 2018-11-22 | 2025-05-29 | Qilu Regor Therapeutics Inc. | GLP-1R agonists and uses thereof |
| CU20210083A7 (es) * | 2019-04-12 | 2022-05-11 | Qilu Regor Therapeutics Inc | Agonistas de glp-1r |
| TWI751585B (zh) | 2019-06-28 | 2022-01-01 | 美商美國禮來大藥廠 | 類升糖素肽1受體促效劑 |
| BR112022007627A2 (pt) | 2019-10-25 | 2022-07-12 | Gilead Sciences Inc | Compostos moduladores do glp-1r |
| CN115335374B (zh) | 2020-01-29 | 2025-05-27 | 吉利德科学公司 | Glp-1r调节化合物 |
| WO2021160127A1 (en) * | 2020-02-13 | 2021-08-19 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| CN115279750B (zh) * | 2020-03-18 | 2024-06-21 | 株式会社Lg化学 | Glp-1受体激动剂、包含该激动剂的药物组合物及其制备方法 |
| MY207021A (en) * | 2020-03-18 | 2025-01-24 | Lg Chemical Ltd | Glp-1 receptor agonist, pharmaceutical composition comprising same, and method for preparing same |
| CN113816948B (zh) * | 2020-06-19 | 2023-08-11 | 江苏恒瑞医药股份有限公司 | 稠合咪唑类衍生物、其制备方法及其在医药上的应用 |
| CR20230066A (es) | 2020-08-06 | 2023-05-29 | Gasherbrum Bio Inc | Agonistas del glp-1 heterocíclicos |
| JP2023538949A (ja) | 2020-08-28 | 2023-09-12 | ガシャーブラム・バイオ・インコーポレイテッド | ヘテロ環ｇｌｐ－１アゴニスト |
| US11851419B2 (en) | 2020-11-20 | 2023-12-26 | Gilead Sciences, Inc. | GLP-1R modulating compounds |
| US20240246959A1 (en) * | 2020-11-27 | 2024-07-25 | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Benzimidazole derivative and preparation method therefor and medical use thereof |
| WO2022192430A1 (en) | 2021-03-11 | 2022-09-15 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
| US12091404B2 (en) | 2021-03-11 | 2024-09-17 | Gilead Sciences, Inc. | GLP-1R modulating compounds |
| WO2022202864A1 (ja) | 2021-03-24 | 2022-09-29 | 塩野義製薬株式会社 | 縮合環を有するｇｌｐ－１受容体作動薬を含有する医薬組成物 |
| CN117279905A (zh) * | 2021-04-21 | 2023-12-22 | 吉利德科学公司 | 羧基-苯并咪唑glp-1r调节化合物 |
| FI4271674T3 (fi) * | 2021-04-21 | 2025-04-23 | Gilead Sciences Inc | Glp-1r:ää moduloivia karboksibentsimidatsoliyhdisteitä |
| AU2022263410B2 (en) * | 2021-04-21 | 2024-08-01 | Gilead Sciences, Inc. | Carboxy-benzimidazole glp-1r modulating compounds |
| TWI843104B (zh) | 2021-05-20 | 2024-05-21 | 美商美國禮來大藥廠 | 類升糖素肽1受體促效劑 |
| CN115703766B (zh) * | 2021-08-10 | 2025-08-08 | 天地恒一制药股份有限公司 | Glp-1受体激动剂及其用途 |
| CN120518588A (zh) * | 2021-08-30 | 2025-08-22 | 杭州德睿智药科技有限公司 | 作为glp1r激动剂的新型芳醚取代杂环类化合物 |
| CN118948849A (zh) | 2021-09-08 | 2024-11-15 | 盐野义制药株式会社 | 用于预防和治疗与抗肥胖作用有关的疾病的药物 |
| HRP20251161T1 (hr) | 2021-09-27 | 2025-11-21 | Terns Pharmaceuticals, Inc. | Benzimidazol karboksilne kisele kao agonisti glp-1r |
| WO2023057414A1 (en) | 2021-10-05 | 2023-04-13 | Astrazeneca Ab | Certain octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators |
| US20250115612A1 (en) | 2021-10-05 | 2025-04-10 | Astrazeneca Ab | Certain 2,5-diazabicyclo[4.2.0]octanes and octahydrofuro[3,4-b]pyrazines as glp-1 receptor modulators |
| US20240417393A1 (en) | 2021-10-05 | 2024-12-19 | Astrazeneca Ab | Certain 2,5-diazabicyclo[4.2.0]octanes as glp-1 receptor modulators |
| TW202334129A (zh) | 2021-10-25 | 2023-09-01 | 美商拓臻製藥公司 | 作為ｇｌｐ—１ｒ促效劑的化合物 |
| US20250066338A1 (en) | 2021-12-16 | 2025-02-27 | Astrazeneca Ab | Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators |
| US20250042882A1 (en) | 2021-12-16 | 2025-02-06 | Astrazeneca Ab | Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators |
| WO2023164050A1 (en) | 2022-02-23 | 2023-08-31 | Terns Pharmaceuticals, Inc. | Compounds as glp-1r agonists |
| EP4491625A1 (en) | 2022-03-08 | 2025-01-15 | Guangzhou Unirise Pharmaceutical Co., Ltd. | Benzo bicyclic compound, and preparation method and application thereof |
| KR20240135652A (ko) * | 2022-05-20 | 2024-09-11 | 쳉두 띠아오 지우홍 파마수티칼 팩토리 | 벤즈이미다졸 또는 아자벤즈이미다졸 화합물, 이의 제조 방법 및 그의 용도 |
| CN119585262A (zh) * | 2022-07-18 | 2025-03-07 | 德睿智药(苏州)新药研发有限公司 | 一种glp-1r激动剂的多晶型物及其制备方法与用途 |
| WO2024041609A1 (zh) * | 2022-08-24 | 2024-02-29 | 广州市联瑞制药有限公司 | 苯并双环类化合物及其制备方法和应用 |
| KR20250047817A (ko) * | 2022-09-06 | 2025-04-04 | 민드랭크 테라퓨틱스 (수저우) 뉴 드러그 리서치 앤 디벨롭먼트 컴퍼니, 리미티드 | Glp-1r 작용제 화합물의 결정다형체 및 이의 제조 방법과 용도 |
| JPWO2024063143A1 (pl) | 2022-09-22 | 2024-03-28 | ||
| KR20250105662A (ko) | 2022-11-11 | 2025-07-08 | 일라이 릴리 앤드 캄파니 | 글루카곤-유사 펩티드 1 수용체 효능제 |
| EP4619098A1 (en) | 2022-11-16 | 2025-09-24 | Eli Lilly and Company | Glucagon-like peptide 1 receptor agonists |
| CN118496200A (zh) * | 2023-02-14 | 2024-08-16 | 成都康弘药业集团股份有限公司 | 吲唑啉酮类化合物及其制备方法和用途 |
| TW202506131A (zh) | 2023-04-07 | 2025-02-16 | 美商拓臻製藥公司 | ＧＬＰ－１Ｒ及ＴＨＲβ激動劑之組合以及其使用方法 |
| WO2024212742A1 (zh) * | 2023-04-10 | 2024-10-17 | 上海研健新药研发有限公司 | 一种glp-1r激动剂，其制备方法和应用 |
| WO2025057134A2 (en) | 2023-09-14 | 2025-03-20 | Ascletis Pharma (China) Co., Limited | Glp-1r agonist and therapeutic method thereof |
| US12291530B1 (en) | 2023-11-24 | 2025-05-06 | Ascletis Pharma (China) Co., Limited | GLP-1R agonist and therapeutic method thereof |
| WO2025158275A1 (en) | 2024-01-24 | 2025-07-31 | Pfizer Inc. | Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist compounds |
| WO2025189141A1 (en) | 2024-03-08 | 2025-09-12 | Annapurna Bio, Inc. | Methods for treating obesity and increasing weight loss |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070004713A1 (en) * | 2000-12-07 | 2007-01-04 | Bernard Barlaam | Therapeutic benimidazole compounds |
| WO2008012623A1 (en) * | 2006-07-25 | 2008-01-31 | Pfizer Products Inc. | Benzimidazolyl compounds as potentiators of mglur2 subtype of glutamate receptor |
| US7799806B2 (en) | 2007-04-04 | 2010-09-21 | Hoffmann-La Roche Inc. | Substituted n-benzyl piperidines as somatostatin receptor modulators |
| EP2552208A4 (en) * | 2010-03-31 | 2014-07-09 | Glaxo Group Ltd | IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS |
| JP2012167027A (ja) * | 2011-02-10 | 2012-09-06 | Shionogi & Co Ltd | Ｎｐｙｙ５受容体拮抗作用を有する縮合ヘテロ環誘導体 |
| WO2015091531A1 (en) | 2013-12-19 | 2015-06-25 | Almirall, S.A. | Imidazolopyrimidin-2-yl derivatives as jak inhibitors |
| AU2017374860B2 (en) | 2016-12-16 | 2021-09-02 | Pfizer Inc. | GLP-1 receptor agonists and uses thereof |
| JP7311228B2 (ja) * | 2017-06-30 | 2023-07-19 | ベイジン タイド ファーマシューティカル カンパニー リミテッド | Ｒｈｏ－関連プロテインキナーゼ阻害剤、それを含む医薬組成物並びにその調製方法及び使用 |
| CU20210083A7 (es) * | 2019-04-12 | 2022-05-11 | Qilu Regor Therapeutics Inc | Agonistas de glp-1r |
| TWI751585B (zh) * | 2019-06-28 | 2022-01-01 | 美商美國禮來大藥廠 | 類升糖素肽1受體促效劑 |
| BR112022007627A2 (pt) * | 2019-10-25 | 2022-07-12 | Gilead Sciences Inc | Compostos moduladores do glp-1r |
| WO2021160127A1 (en) | 2020-02-13 | 2021-08-19 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| CN115279750B (zh) * | 2020-03-18 | 2024-06-21 | 株式会社Lg化学 | Glp-1受体激动剂、包含该激动剂的药物组合物及其制备方法 |
| US20230382899A1 (en) | 2020-10-14 | 2023-11-30 | Qilu Regor Therapeutics Inc. | Crystal forms of glp-1r agonists and uses thereof |
-
2020
- 2020-12-01 WO PCT/KR2020/017405 patent/WO2021112538A1/en not_active Ceased
- 2020-12-01 HU HUE20895723A patent/HUE070634T2/hu unknown
- 2020-12-01 ES ES20895723T patent/ES3010351T3/es active Active
- 2020-12-01 PL PL20895723.3T patent/PL4069686T3/pl unknown
- 2020-12-01 US US17/780,486 patent/US12421205B2/en active Active
- 2020-12-01 EP EP20895723.3A patent/EP4069686B1/en active Active
- 2020-12-01 CN CN202080084248.4A patent/CN114761395B/zh active Active
- 2020-12-01 KR KR1020200165832A patent/KR20210069000A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US12421205B2 (en) | 2025-09-23 |
| CN114761395B (zh) | 2024-11-15 |
| EP4069686B1 (en) | 2025-01-22 |
| EP4069686C0 (en) | 2025-01-22 |
| US20230051318A1 (en) | 2023-02-16 |
| ES3010351T3 (en) | 2025-04-02 |
| KR20210069000A (ko) | 2021-06-10 |
| WO2021112538A1 (en) | 2021-06-10 |
| HUE070634T2 (hu) | 2025-06-28 |
| EP4069686A4 (en) | 2022-11-09 |
| CN114761395A (zh) | 2022-07-15 |
| EP4069686A1 (en) | 2022-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL4069686T3 (pl) | Agonista receptora glp-1 | |
| PT4058445T (pt) | Agonista do recetor glp-1 e sua utilização | |
| IL279300A (en) | 1-GLP agonist receptors and their use | |
| IL279224A (en) | 1-GLP agonist receptors and their use | |
| IL287166A (en) | A pyrazolopyridine derivative with an agonistic effect on the glp-1 receptor | |
| IL323922A (en) | Melanocortin-4 receptor agonists | |
| ZA201804997B (en) | Triple glucagon/glp-1/gip receptor agonist | |
| GB201911187D0 (en) | Receptor | |
| GB2551945B (en) | Novel GLP-1 receptor agonist peptides | |
| GB201816639D0 (en) | GLP-1 Receptor Antagonist | |
| GB202011604D0 (en) | GLP-1 receptor antagonists | |
| GB201910515D0 (en) | GLP-1 Receptor antagonists | |
| GB201816650D0 (en) | GLP-1 Receptor antagonists | |
| GB201903985D0 (en) | GLP receptor agonists | |
| HK40086535A (en) | Glp-1 receptor antagonists | |
| GB201817943D0 (en) | Galanin-2 receptor agonists | |
| HK40040824A (en) | Glucagon receptor antagonists |